“Opyl is seeking to solve PR&WD points of trial failure by applying PA and AI”
BioSpectrum Asia|December 2020
A real world data is a boon to improve health and wellness. Optimising data assets through digital activation can advance healthcare technologies. Opyl, an Australian health data analytics company enables biopharma and health organisations to access emerging AIassisted technologies with its professional guidance to improve healthcare design, development and delivery. Leveraging social media, the team is assisting patients, healthcare providers and researchers in mining social media data insights (with informed consent) using AI applications. This has been particularly important during COVID-19, as Opyl noted a 188 per cent increase in pandemic-related clinical and research findings being discussed and shared by medical researchers on social media channels. In an interaction with BioSpectrum Asia, Michelle Gallaher, CEO of Opyl, Australia with expertise on healthcare marketing, data science and knowledge on social media health trends shared more professional guidance based on predictive analytics (PA) for improvised healthcare deliveries. Edited excerpts;
Hithaishi C Bhaskar
“Opyl is seeking to solve PR&WD points of trial failure by applying PA and AI”

How do you describe the predictive analytics relationship with pharmaceutical industry and in streamlining healthcare deliveries?

Wanting to know the future is a natural human endeavour, especially in healthcare. Investors, drug developers and patients all have an intense interest in knowing if a clinical trial will deliver a catalyst event; reach its primary endpoint; and deliver on its promise. Waiting ten years or more for a result demands patience and the fortitude to risk vast financial investments. However, what if we could predict the outcome of a clinical trial before it has even been launched. Predictive analytics (PA) and artificial intelligence (AI) is the evidence-based ‘crystal ball’ that is transforming health industries.

Michelle Gallaher, CEO, Opyl, Australia

Despite the increasing number of clinical trials registered annually, over the past 20 years the number of drugs and devices that make it to full registration stubbornly remains a fraction of their potential. Last year the Food and Drug Administration (FDA) approved 48 new drugs from 318,901 registered clinical trials. The year before that, the FDA hit a record of 59 approved drugs.

Currently, oncology drugs only have a 3.4 per cent chance of successfully achieving registration, while in previous years the probability of success has been as low as 1.7 per cent. As each year passes, billions of dollars invested into research and development fail to deliver a return. Mistakes in the design of a drug or device trial are frustratingly common, usually reported as drug failure rather than poor expertise, regulatory micromanagement, or lax patient enrolment and follow up.

هذه القصة مأخوذة من طبعة December 2020 من BioSpectrum Asia.

ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.

هذه القصة مأخوذة من طبعة December 2020 من BioSpectrum Asia.

ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.

المزيد من القصص من BIOSPECTRUM ASIA مشاهدة الكل
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
BioSpectrum Asia

Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time

US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
BioSpectrum Asia

Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers

Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
BioSpectrum Asia

Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine

Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
BioSpectrum Asia

Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis

US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singapore designs novel gene therapy offering hope for epilepsy patients
BioSpectrum Asia

Singapore designs novel gene therapy offering hope for epilepsy patients

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Spider venom heart drug moves to clinical trials in Australia
BioSpectrum Asia

Spider venom heart drug moves to clinical trials in Australia

A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).

time-read
1 min  |
BioSpectrum Asia Nov 2024
India develops portable ultrasound scanner for sports injury diagnosis
BioSpectrum Asia

India develops portable ultrasound scanner for sports injury diagnosis

A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Integris appoints medtech veteran Probir Das as new CEO
BioSpectrum Asia

Integris appoints medtech veteran Probir Das as new CEO

Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Clarity Pharma promotes Michelle Parker to CEO
BioSpectrum Asia

Clarity Pharma promotes Michelle Parker to CEO

Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
BioSpectrum Asia

Dr Makoto Sugita steps in as President of Nxera Pharma Japan

Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.

time-read
1 min  |
BioSpectrum Asia Nov 2024